Aethlon Medical Inc. has announced an important update regarding its merger with North Immunology, a move that could reshape its business landscape. The company filed a report on November 16, 2026, detailing the merger agreement and the implications for its future.
Aethlon Medical, Inc., incorporated in Nevada, operates under the SIC code 2834, which pertains to pharmaceutical preparations. The company trades on the Nasdaq under the ticker symbol AEMD. Recently, it has been active in filing various reports, including a 10-Q and several 8-K forms, indicating a period of significant corporate activity.
The filing reveals that Aethlon Medical entered into a merger agreement with North Immunology on September 17, 2026. This agreement includes two phases: the first merger will see Nighthawk Merger Sub Corp. merge with North Immunology, making it a wholly owned subsidiary of Aethlon. Following this, North Immunology will merge with Nighthawk Second Merger Sub, LLC, with the latter surviving the transaction. This structure aims to streamline operations and enhance the combined entity's market position.
On November 16, 2026, North Immunology provided an updated investor presentation, which is attached to the filing as Exhibit 99.1. This presentation is intended for use in meetings with investors, indicating that Aethlon is actively engaging with the investment community to discuss the merger and its potential benefits.
The implications of this merger are significant for Aethlon Medical, as it may affect various stakeholders, including investors, employees, and customers. Investors will be particularly interested in how this merger might enhance the company’s product offerings and market reach within the pharmaceutical industry. The merger could also lead to new opportunities for growth and innovation in drug development.
Looking ahead, the filing does not specify the immediate next steps following this update. However, it indicates that further information will be provided in future filings, including a registration statement on Form S-4 that will contain a proxy statement and prospectus related to the merger.
Read Next
Ring Energy CFO Johl Sundip Singh Acquires 57,923 Shares
Sartori Juan acquires shares in Gold.com, Inc. via stock grant
Skates Spenser Reports Stock Transactions in SEC Filing
York Space Systems CFO Acquires 6,043 Shares in Stock Deal
H.B. Fuller announces leadership changes amid acquisition
Evans David C acquires 755 shares of Cardinal Health Inc








